August 19, 2008

The Cystic Fibrosis (CF) Market is Poised for Significant Change. Will New Agents Emerge As First-Line Therapies?

Research and Markets ( has announced the addition of Decision Resources, Inc.'s new report "Cystic Fibrosis: Will New Agents Emerge as First-Line Therapies?" to their offering.

The cystic fibrosis (CF) market is poised for significant change. The next generation of CF treatments all target the central mechanism responsible for organ damage in CF. These agents, as one thought leader states, "represent the closest we have come to a cure for CF" and will almost certainly bring about a change in the treatment algorithm of the disease. As a result, new market leaders will emerge, and current first-line therapies will find themselves relegated to second- or third-line options.

Get the Answers You Need to Shape Your Strategy

Physicians use a variety of medications and non-pharmacological treatments to address the needs of:

-- CF patients. What are the strengths and weaknesses of these treatments? Which work best in specific subpopulations? Do thought leaders believe these treatments will still have a role in the treatment algorithm over the next five to ten years?

-- Several drugs with trusted and novel mechanisms of action are in development for CF.

What new agents are in development? What are thought leaders' opinions of the potential of these agents in the treatment of CF? What impact will these agents have on treatment algorithms and the CF market?

-- Emerging agents target the central mechanism responsible for organ damage in CF and have the potential to be disease modifying rather than just treating symptoms. What unmet needs remain in drug development? Will the formulations of these emerging therapies improve patient compliance? What more is required to effectively treat the paediatric subpopulation?

Overview of - CF: disease development, symptoms, complications, and methods for diagnosis.

-- Epidemiology: disease definition; incidence by race; growth in the number of prevalent cases.

-- Current therapies: mucolytics, antibiotics, pancreatic enzyme replacement therapy, as well as thought leaders' opinions on where these agents fit into the treatment algorithm.

-- Emerging therapies: strengths and weaknesses of agents in development; novel mechanisms of action; an analysis of market position for these agents.

-- CF market: details on the 2007 market and prescribing trends.

-- Outlook: the impact of novel agents on the CF market.

-- Orphan Disease Series: As competition increases in larger disease states, companies are turning to orphan diseases that offer substantial pricing advantages and lower regulatory hurdles because of high unmet need. The Orphan Disease Series provides critical market information, including disease prevalence, profi les of marketed and emerging agents, and insight into the prescribing choices of disease specialists for diseases with smaller patient populations. These reports will help you to maximize the potential of your agents in these challenging markets, including the regulatory benefits available and the potential for partnership with charitable organizations.

 Key Topics Covered: Executive Summary Strategic Considerations Stakeholder Implications Introduction Overview of Cystic Fibrosis Anatomy of the Lung The Role of CFTR in the Development of Cystic Fibrosis Diagnosis of Cystic Fibrosis Symptoms and Complications Pulmonary Symptoms/Complications Pancreatic Symptoms/Complications Epidemiology and Patient Populations Overview Disease Defi nition Current Treatments Nebulized Mucolytics Genentech/Roche's Pulmozyme Hypertonic Saline Comparison of Pulmozyme and Hypertonic Saline Inhaled Antibiotics Pfi zer's Zithromax Pancreatic Enzyme Replacement Therapy Emerging Therapies PTC Therapeutics' PTC124 Vertex Pharmaceuticals' VX770 Inspire Pharmaceuticals' Denufosol Tetrasodium Gilead's Cayston (Inhaled Aztreonam) Novartis/Nektar's Tobramycin Inhaled Powder New Formulations of Pancreatic Enzymes 2007 Cystic Fibrosis Market and Outlook for Emerging Therapies Appendix A Incentive Programs for the Research, Development, and Marketing of Orphan Drugs FDA Expanded Market Exclusivity Tax Credits Support During the Drug Approval Process Grants EMEA Private Organization Incentives Appendix B Epidemiology Methodology Incidence Prevalence 

  Companies Mentioned: - Abbott - Aerovance - Altus Pharmaceuticals - Axcan - Bayer - Cellular Sciences - Copernicus Therapeutics - Eurand - Genentech - Gilead - GlaxoSmithKline - Immunsystem - Inspire Pharmaceuticals - Johnson & Johnson - Lantbio - Nektar - Novartis - Novo Nordisk - Parion Sciences - Pfizer - PTC Therapeutics - Roche - Solvay - Sucampo Pharmaceuticals - Vertex Pharmaceuticals 

For more information visit